Jian Zhou: The Scientist Who Helped Make the HPV Vaccine Possible

He lived long enough to see the vaccine reach clinical trials — but not long enough to see how far it would eventually go.

⏱ In 30 Seconds

✓ Jian Zhou was a Chinese-born virologist who worked with Ian Frazer, Xiao-Yi Sun and colleagues on research that helped make HPV vaccination possible.
✓ In 1991, Zhou was first author of a landmark study showing that HPV16 capsid proteins could assemble into virus-like particles (VLPs), a crucial principle behind modern HPV vaccines.
✓ Zhou died unexpectedly in 1999 at just 42 years old, when vaccine development based on the research had already reached clinical trials.
✓ He never saw HPV vaccines become a global cancer-prevention tool. Ian Frazer later described Zhou as an “equal partner” in much of the HPV vaccine development work.

In 2006, one of the most remarkable ideas in cancer prevention became a medical reality.

A vaccine against human papillomavirus (HPV) became available. HPV causes nearly all cervical cancers and also contributes to anal, oropharyngeal, vaginal, vulvar and penile cancers.

This was a vaccine designed not to treat cancer after it appeared, but to prevent infection with a virus that could cause cancer years or even decades later.

For Australian immunologist Ian Frazer, it was the culmination of years of research. But one of the scientists who had helped make that moment possible, Jian Zhou, was no longer there to see it.

Seven years earlier, on 10 March 1999, Zhou had died unexpectedly following a brief illness while in Hangzhou, China. He was only 42.

At the time of his death, vaccine development arising from the research had already moved beyond the laboratory and into clinical trials.

Zhou lived long enough to see that the idea might become a real vaccine. What he never saw was how far it would eventually go.

A Virologist Meets an Immunologist

Jian Zhou’s path to the HPV vaccine began far from Australia.

Born in China in 1957, Zhou trained in medicine and developed expertise in molecular virology. His scientific career eventually took him to Cambridge in the United Kingdom.

It was there, in 1989, that he met Ian Frazer.

The two scientists approached HPV from different directions. Frazer was a physician and immunologist interested in HPV infection, immunity and cervical cancer, while Zhou was a molecular virologist with expertise in manipulating viral genes and proteins experimentally.

Their complementary expertise would prove important.

When Frazer moved to Queensland to continue his research, Zhou joined him, along with Xiao-Yi Sun, Zhou’s wife and scientific collaborator.

Sun should not be remembered simply as Zhou’s wife. She was herself a researcher and became directly involved in the experimental work that helped establish the scientific basis for HPV vaccination.

Professor Margaret Stanley, a leading HPV researcher who knew Zhou and Sun from their time in Cambridge, later remembered the couple as a particularly effective scientific partnership.

“The two of them together were an extraordinary team.”

— Margaret Stanley, Queen Mary University of London interview, 2021

Stanley’s recollections also reveal something of Zhou’s personality as a scientist.

He was intensely focused on producing large quantities of HPV’s major capsid protein, L1.

“He was absolutely obsessed with the idea that you had to make a lot of the coat protein L1.”

— Margaret Stanley, Queen Mary University of London interview, 2021

That scientific obsession would prove remarkably important.

A Virus That Wouldn’t Cooperate

By this time, scientists increasingly understood that particular types of HPV were strongly associated with cervical cancer.

HPV Is Not Just One Virus

HPV is not one virus but a family of around 200 known types. Most are harmless, while a smaller group known as high-risk HPV can cause cancer if infection persists.

Among them, HPV16 and HPV18 are particularly important. Together they cause around 70% of cervical cancers.

That helps explain why Zhou and his colleagues were so interested in HPV16. They were not studying just another virus type — they were working on one of the most important cancer-causing HPVs.

But identifying the cause of a cancer and finding a way to prevent it are very different achievements.

HPV presented another challenge.

Its life cycle is closely linked to the differentiation of epithelial cells, making the virus unusually difficult to reproduce using conventional laboratory systems.

Researchers therefore faced a deceptively simple question:

Could they show the immune system what HPV looked like without having to use infectious HPV itself?

The answer lay in the proteins forming the virus’s outer shell.

Zhou became particularly interested in L1, the major capsid protein of HPV.

Stanley later credited Zhou directly with making the early virus-like particles that helped move the field forward.

Building a Virus That Wasn’t a Virus

In 1991, Jian Zhou, Xiao-Yi Sun, Deborah Stenzel and Ian Frazer published an important experiment in the journal Virology.

Zhou was the first author.

The researchers engineered a recombinant vaccinia virus to express two capsid proteins from HPV type 16, L1 and L2.

Inside cells producing both proteins, the proteins assembled into structures approximately 40 nanometres across that resembled HPV particles.

These structures were virus-like particles, or VLPs: they reproduced important features of the viral shell without being infectious HPV.

The VLP Principle

HPV capsid proteins
↓
Self-assembly
↓
Virus-like particle
↓
Viral surface without infectious HPV genome
↓
Immune recognition without HPV infection

The principle was elegant: a VLP could reproduce important structural features of the outside of HPV without requiring the infectious viral genome inside it.

In effect, researchers could potentially teach the immune system to recognise HPV without exposing someone to infectious HPV.

The researchers themselves recognised the possibility. Their 1991 paper suggested that producing HPV-like particles in this way could provide a safe source of material for vaccine development.

A laboratory experiment had opened a route towards a vaccine.

But Were These the First Virus-Like Particles?

No. Zhou and his colleagues did not invent VLPs themselves.

Scientists had already used similar non-infectious particles in hepatitis B vaccines before the 1991 HPV study.

What Zhou and his colleagues achieved was to make this idea work for HPV — a virus that had been notoriously difficult to reproduce in the laboratory.

That distinction makes their achievement no less important. In fact, it makes it clearer: they helped turn the VLP principle into a practical route towards preventing HPV — and ultimately, preventing cancer.

But there was still an enormous distance between seeing microscopic particles in a laboratory and preventing cancer in millions of people.

From an Experiment to a Vaccine

Scientific discoveries rarely move directly from the laboratory bench to the clinic. The HPV vaccine was no exception.

The VLP approach required further development. Researchers needed to establish that the particles could generate an appropriate immune response, manufacturing methods had to be developed, and safety and efficacy had to be demonstrated.

Most importantly, clinical trials had to show that vaccination could prevent HPV infection and the precancerous changes that can follow it.

The eventual HPV vaccines were not the achievement of a single laboratory. Other research groups made important contributions to papillomavirus VLP research, while biotechnology and pharmaceutical companies played essential roles in manufacturing, clinical development and large-scale testing.

Within that broader history, the importance of the Queensland work is clear. The 1991 study demonstrated that HPV16 capsid proteins could assemble into virus-like particles and explicitly recognised their potential as vaccine material.

Zhou and Frazer were also named as inventors on intellectual property covering papillomavirus vaccine technology arising from their work.

And Zhou lived long enough to see the idea begin to leave the laboratory.

By 1999, vaccine development based on the research had reached clinical trials.

For a scientist, that represented an extraordinary transition. Something that had begun with viral proteins inside laboratory cells was now being tested as a way of preventing cancer in people.

But a clinical trial is still an experiment. There was no guarantee about how the story would end.

A Career Cut Short

On 10 March 1999, Jian Zhou died in Hangzhou following a brief illness. He was 42 years old.

At the time, he was Lions Principal Research Fellow and head of the Papillomavirus Virology Unit at the University of Queensland’s Centre for Immunology and Cancer Research.

Zhou was still in the middle of his scientific career. His research was continuing, and the vaccine technology he had helped create had already reached clinical trials.

He had seen an experimental idea begin to move towards a real vaccine. What he could not know was whether it would ultimately succeed.

Would the vaccine protect people? Would regulators approve it? Would governments adopt it? And would protection against HPV eventually translate into fewer cancers across entire populations?

Those answers still lay in the future.

Shortly after his death, Frazer remembered Zhou not only as an accomplished scientist, but also as a colleague and friend.

Seven Years Later

In 2006, HPV vaccination entered clinical use.

A technology that had begun years earlier with viral proteins and virus-like particles could now be used to prevent infection with some of the HPV types responsible for cervical cancer.

Its significance went beyond conventional cancer treatment: vaccination could intervene before cancer existed, preventing infection with important cancer-causing HPV types and interrupting the biological chain of events that can ultimately lead to cancer.

Jian Zhou never saw that moment, or what came next.

The Partner Who Remembered Him

As HPV vaccination became an international success, Ian Frazer became its best-known Australian scientific figure.

Recognition and major scientific awards followed.

But Frazer did not describe the achievement as his alone.

In 2008, while accepting the prestigious Balzan Prize, Frazer used part of his speech to remember the colleague who could no longer stand beside him.

“Dr Jian Zhou … was an equal partner in much of the work on HPV vaccine development.”

— Ian Frazer, Balzan Prize Acceptance Speech, 2008

Frazer went further, explaining that Zhou was no longer there to receive the public acknowledgement that he would have shared had he lived.

Jian Zhou’s story should not be turned into a tale in which one scientist took another scientist’s credit. Zhou and Frazer brought different expertise to the same scientific problem, while Xiao-Yi Sun and other researchers contributed directly to the experimental work.

Other laboratories made important advances of their own, and years of industrial development and clinical trials were required before the technology could become a vaccine. The history does not need a villain; it is a story of scientific collaboration whose full impact took years to emerge.

Two scientists helped begin a journey, but only one of them lived long enough to see where it led.

Why This Discovery Still Matters

The scale of what followed would have been difficult to imagine when Zhou, Sun, Frazer and their colleagues were examining virus-like particles in the laboratory.

HPV vaccination became one of the major tools for preventing cervical cancer. The underlying idea is extraordinary:

Vaccination against an infectious agent can prevent cancers that might otherwise appear decades later.

Could VLPs Treat Cancer Too?

The success of HPV vaccination also raised another question: could VLP technology be adapted to treat disease that was already present?

Researchers later tested modified VLPs carrying HPV cancer-related proteins, including in women with precancerous cervical lesions. These approaches could stimulate immune responses, but they did not become established cancer treatments.

The distinction is important. Today’s HPV vaccines prevent cancer; they do not treat existing HPV infections or cancers.

Meanwhile, the impact of prevention continues to grow. The World Health Organization has adopted a global strategy to eliminate cervical cancer as a public-health problem, and Australia is among the countries closest to achieving that goal.

There is a remarkable connection here. More than three decades ago, Jian Zhou was working with Ian Frazer, Xiao-Yi Sun and colleagues in Queensland on proteins from a cancer-causing virus. Today, the country where much of that research took place is moving towards making cervical cancer extraordinarily rare.

Zhou never saw HPV vaccination become routine or cervical cancer elimination become a realistic goal. But he did see the experiment leave the laboratory: when he died in 1999, the vaccine was already being tested in people.

Science can work on a timescale longer than a research project, a career or even a scientist’s life.

Jian Zhou’s work travelled extraordinarily far.

A Personal Reflection

While writing this story, I found myself thinking about how science remembers people like Jian Zhou.

The Nobel Prize, by its rules, cannot normally be awarded posthumously. Yet some discoveries take decades to reveal their full significance. By the time a discovery transforms medicine or changes millions of lives, the scientist who helped make it possible may no longer be there to receive that recognition.

I wished there were other ways to honour scientists whose discoveries outlive them.

Then I discovered that, in Jian Zhou’s case, there is one.

The Australian Academy of Health and Medical Sciences established the Jian Zhou Medal in his honour. Awarded annually, it recognises rising stars of Australian health and medical science who are making a significant impact in translational medical research.

There is something particularly fitting about that choice. Zhou himself was only 42 when he died, with some of the greatest consequences of his research still in the future. Today, an award bearing his name recognises other researchers who are still relatively early in their careers — at a time when the eventual impact of their own work may also be impossible to predict.

The medal was made possible by the Frazer Family Foundation and is designed and minted by the Royal Australian Mint. Fittingly, it carries an illustration of the virus-like particle that Zhou helped create.

Jian Zhou never saw the full impact of the vaccine his research helped make possible. But his name now lives on not only through that discovery, but through new generations of Australian medical researchers recognised in his honour.

And every HPV vaccination given today carries forward part of the work he left behind.

Landmark Discovery

The 1991 work by Jian Zhou, Xiao-Yi Sun, Deborah Stenzel and Ian Frazer demonstrated that expression of HPV16 capsid proteins could produce virus-like particles resembling the viral shell.

That finding helped establish a practical route towards vaccines that could expose the immune system to key HPV structures without using infectious HPV.

Zhou J, Sun XY, Stenzel DJ, Frazer IH.
Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.
Virology. 1991;185(1):251–257.

Key Findings

✓ HPV16 capsid proteins L1 and L2 can assemble into virus-like particles.
✓ These particles reproduce important structural features of HPV without requiring infectious HPV.
✓ Jian Zhou was first author of the landmark 1991 Virology study.
✓ Xiao-Yi Sun was an important scientific collaborator in the experimental work.
✓ Ian Frazer later publicly described Zhou as an equal partner in much of the HPV vaccine development work.

Continue Reading

This article is intended for general educational purposes. Readers seeking a more technical account should consult the original publications and specialist literature listed above.

thebiostories